Q4 2024 Cibus Inc Earnings Call Transcript
Key Points
- Cibus Inc (CBUS) is making significant progress in its transformation from an agricultural trait development company to a commercial trait company, with a focus on gene-edited productivity traits.
- The company's proprietary Rapid Trait Development System (RTDS) allows for precise gene editing, making traits indistinguishable from those developed via conventional breeding, which is advantageous from a regulatory perspective.
- Cibus Inc (CBUS) has established collaborations with major rice seed companies in North and Latin America, representing approximately 40% of accessible rice acres in these regions.
- The company is seeing promising results from field trials, particularly in rice and canola, which are moving towards commercialization.
- Cibus Inc (CBUS) is well-positioned to benefit from favorable regulatory changes in the EU, which could expand the market for gene-edited products.
- Cibus Inc (CBUS) reported a net loss of $25.8 million for the fourth quarter of 2024, although this is an improvement from the previous year's loss.
- The company is reliant on existing cash and cash equivalents to fund operations into the late third quarter of 2025, highlighting potential financial constraints.
- There is uncertainty regarding the timing of commercialization for some of Cibus Inc (CBUS)'s products, particularly in the EU market.
- The company is still in the process of developing its Soybean platform, which is crucial for accessing a substantial market.
- Cibus Inc (CBUS) is facing challenges in achieving cost reductions, although some progress has been made in streamlining operations.
Good afternoon and welcome to the Cibus fourth-quarter 2024 results conference call.
(Operator Instructions) Also note, today's event is being recorded.
At this time, I'd like to turn the conference over to Mr. Carlo Broos, Interim Chief Financial Officer. Sir, please go ahead.
Thank you and good afternoon. We'd like to thank you for taking time to join us for Cibus' fourth-quarter 2024 financial results and business [update] call and webcast.
Presenting with me, today, is Peter Beetham, Co-Founder, Interim Chief Executive Officer, President, and COO. Greg Gocal, our Chief Scientific Officer, will also be on today's call, for participation during the Q&A session.
Before we begin the call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results, and future operational goals, and industry prospects are forward-looking and may be subject to a number of risks and uncertainties that could cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
